Curanex Pharmaceuticals Inc filed a Form S-1 registration statement for an initial public offering on 2024-10-16. It has amended it 6 times. It filed its final prospectus on 2025-08-26, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our Common Stock was approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CURX.”From the 424B4 filed 2025-08-26
Offering price
Negotiations with the Underwriters determined the initial public offering price of $4.00 per share in the IPO, which may bear no relationship to the market price of our shares of Common Stock after the IPO. the Underwriters and may not be indicative of prices that will prevail in the open market following this Offering.From the 424B4 filed 2025-08-26
Use of proceeds
We intend to use the net proceeds received from this underwritten offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology, and for other working capital and general corporate purposes.From the 424B4 filed 2025-08-26
Net loss or income
As a result of the factors mentioned above, we reported a net loss of $224,343 for the nine months ended September 30, 2024, compared to a net loss of $6,527 for the nine months ended September 30, 2023.From the S-1/A filed 2024-11-27
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-10-16 | Registration statement filed | S-1 |
| 2024-11-01 | Registration statement amended | S-1/A |
| 2024-11-27 | Registration statement amended | S-1/A |
| 2025-02-14 | Registration statement amended | S-1/A |
| 2025-03-17 | Registration statement amended | S-1/A |
| 2025-07-01 | Registration statement amended | S-1/A |
| 2025-07-18 | Registration statement amended | S-1/A |
| 2025-08-26 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-08-26 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Curanex Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.